HCP
MRNA icon

Hexagon Capital Partners’s Moderna MRNA Stock Holding History

Hexagon Capital Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-449
Closed -$12.7K – 1082
2025
Q1 		$12.7K Sell
449
-6
-1% -$213 ﹤0.01% 895
2024
Q4 		$18.9K Buy
455
+125
+38% +$5.97K ﹤0.01% 803
2024
Q3 		$22.1K Buy
330
+20
+6% +$1.84K ﹤0.01% 682
2024
Q2 		$36.7K Buy
310
+1
+0.3% +$127 0.01% 505
2024
Q1 		$33K Sell
309
-301
-49% -$30.3K 0.01% 529
2023
Q4 		$60.6K Buy
610
+394
+182% +$33.1K 0.01% 366
2023
Q3 		$22.3K Sell
216
-54
-20% -$6.02K 0.01% 528
2023
Q2 		$32.8K Sell
270
-16
-6% -$2.13K 0.01% 450
2023
Q1 		$44K Sell
286
-8
-3% -$1.32K 0.01% 381
2022
Q4 		$52.9K Sell
294
-29
-9% -$4.74K 0.02% 345
2022
Q3 		$38K Buy
323
+78
+32% +$11.8K 0.01% 448
2022
Q2 		$35K Buy
245
+36
+17% +$5.15K 0.01% 430
2022
Q1 		$36K Buy
209
+200
+2,222% +$33.7K 0.01% 416
2021
Q4 		$2K Hold
9
– – ﹤0.01% 769
2021
Q3 		$4K Buy
+9
New +$3.32K ﹤0.01% 704

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Hexagon Capital Partners's MRNA Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Moderna (MRNA) in Q2 2025, closing a stake of 449 shares — an estimated $12.7K sold.

Hexagon Capital Partners first reported a position in MRNA in Q3 2021 and held it in 15 quarters. The position peaked at $60.6K in Q4 2023. 674 funds tracked by Wall St. Rank hold MRNA as of Q2 2025.

  • Hexagon Capital Partners reported no remaining Moderna position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 449 Moderna shares in Q2 2025, an estimated $12.7K.
  • Hexagon Capital Partners first reported a position in Moderna in Q3 2021 and held it in 15 quarters.
  • Hexagon Capital Partners's Moderna position peaked at $60.6K in Q4 2023.
  • 674 funds tracked by Wall St. Rank held Moderna as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.